ABSTRACT
BACKGROUND

1
It is now half a century since the French cardiologist François Dessertenne published his 2 original report of a characteristic polymorphic ventricular tachycardia and coined the phrase 3 'torsades de pointes' a (TdP) or 'twisting of the points' to describe its ECG appearance. (1) 4
This uncommon arrhythmia characteristically occurs in self-terminating bursts, causing 5 dizziness or syncope and occasionally convulsions, but can occasionally degenerate into 6 ventricular fibrillation, resulting in sudden cardiac death.
7
Torsades occurs when there is delayed ventricular repolarisation with associated triggered 
14
The QT interval
15
The QT interval extends from the onset of the QRS complex to the end of the T wave and 
10
Antiarrhythmics are also used in patients likely to have other risk factors.
11
Assessing risk
12
The extent of QT prolongation is one of several important risk factors for the development of 
21
It is also necessary to take account of the heart rate, because the QT interval shortens as 22 heart rate increases. Although TdP due to aLQTS is uncommon in patients with tachycardia,
23
accurate assessment of delayed repolarisation is still important because of the risk of TdP in 24 the event of subsequent bradycardia or pauses. Various formulae are available to provide a
25
QT interval corrected to a heart rate of 60/min (QTc 
18
More recently a heart rate-QT interval nomogram has been described for risk stratification
19
( Figure 1 ). This method is attractive because avoids the need for correction formulae and is 20 based on heart rate rather than RR interval. Because the relationship between QT interval,
21
heart rate and risk is uncertain in those with more rapid heart rates, an interrupted 22 nomogram line is used for heart rates above 105 /min. 
19
Drug interactions are important precipitants of torsades and avoiding these is essential.
20
These may be pharmacokinetic, for example via inhibition of metabolism ( 
6
Because magnesium does not affect the QT interval, it is not possible to measure response. should be terminated by electrical cardioversion. (9) It is more typical, however, for TdP to 10 occur in recurrent self-terminating bursts. Under these circumstances treatment is directed at 11 stabilising the myocardium using magnesium sulphate and by shortening repolarisation by 12 increasing heart rate using chronotropic drugs such as isoproterenol (isoprenaline) or 13 cardiac pacing.(20) Benefit may also be obtained using antiarrhythmic drugs, although some 14 of these, especially class 1a and class 3 agents, may worsen the arrhythmia.
15
As for isolated QT prolongation, responsible agent(s) should be discontinued and modifiable
16
risk factors such as hypokalaemia, hypomagnesaemia and hypoxia should be addressed.
17
Several sources recommend that serum potassium is maintained in the high normal range
18
(4.5-5.0 mmol/L), although evidence is limited. (9, 20) 
14
Magnesium therapy is simple and relatively safe to administer. Recommended doses in the
15
UK are shown in 14 Promising results were obtained for clonidine and dexmedetomidine, with both drugs
shortening the QT interval and reducing the incidence of TdP in a rabbit model of aLQTS.
16
(47)
17
The anti-ischaemic agent ranolazine blocks the late sodium current which is responsible for including obtaining a family history focusing on syncope, epilepsy and/or sudden death.
5
Cardiological and genetic evaluation will then be required for patients to confirm evidence for 6 the condition and for the family members of those in whom cLQTS is confirmed. (49) 7
In view of the widespread use of QT prolonging drugs, it is important that these are not 
